IDI, Inc. COGT 深 滬
等待開盤 07-17 09:30:00 美东时间
11.86
+0.360
+3.13%
華盛通- 最 高11.975
- 今 開11.65
- 成交量 238.41万股
- 最 低 11.60
- 昨 收 11.50
- 總市值 13.52亿
- 52周最高 12.61
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.72
- 委 比 -78.25%
- 總股本 1.14亿
- 歷史最高 27.80
- 量 比 0.42
- 振 幅 3.26%
- 歷史最低 3.67
- 每 手 1
- 風險率 2.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TENCENT MUSIC ENTERTAINMENT(1698.HK)2Q25 PREVIEW:SLIGHT PROFIT BEAT; STRENGTHENED REFINED OPERATIONS ON SOLIDIFIED KEY EDGES
We model 2Q25 12% YoY topline contributed by solid 19% YoY music, both meeting ...
07-16 12:07
美股周涨跌榜 | 加密货币概念股SharpLink周涨71%；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高
加密货币股SharpLink周涨71%；MP周涨超41%，公司与美国国防部签署战略合作协议；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高>>
07-12 10:03
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
Cogent Biosciences conducted an underwritten public offering of 22,222,223 shares at $9.00 per share, raising approximately $200 million before expenses. An additional 3,333,333 shares can be purchased underwriters option. Proceeds will fund development and commercial preparation of bezuclastinib, a KIT inhibitor for systemic mastocytosis and gastrointestinal stromal tumors, as well as other therapies. J.P. Morgan, Leerink Partners, and Guggenhei...
07-09 01:36
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
Market-Moving News for July 7th
TSLA: -6% | Tesla shares are trading lower after CEO Elon Musk said he would launch a political party. COGT: 25% | Cogent Biosciences shares are trading higher after the company announced topline results
07-07 19:22
Cogent Biosciences Announces Topline Results From Part 2 Of The SUMMIT Trial Of Bezuclastinib For Non-advanced Systemic Mastocytosis, Demonstrating Clinically Meaningful And Highly Statistically Significant Improvements Across The Primary And All Key Secondary Endpoints
Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with
07-07 19:09
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
Cogent Biosciences announced positive results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM). The trial demonstrated statistically significant improvements in symptom scores, mast cell burden, and safety profiles. Bezuclastinib achieved a mean TSS reduction of 24.3 points vs. 15.4 points for placebo, with 87.4% of patients showing ≥50% reduction in serum tryptase. The company plans to submit ...
07-07 11:06
每日数字货币动态汇总（2025-06-30）
小程序：每日数字货币动态汇总 1. 特朗普：加密货币创造就业机会，比特币减轻了美元压力 美国总统特朗普表示，加密数字货币是一种非常有意思的东西，我们已经打造了一...
06-30 10:56
Needham Reiterates Hold on Cogent Biosciencesto Hold
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) from Hold to Hold.
06-17 18:47
